Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P06 - Early Stage/Localized Disease/Ablative Therapies - Surgery
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
P06.04 - Clinical Outcomes and Pathological Characteristics of Resected ALK+ Lung Adenocarcinoma: A Single Center Retrospective Analysis
00:00 - 00:00 | Presenter: Zihua Zou
- Abstract
Loading...
-
+
P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P40.01 - Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study
00:00 - 00:00 | Presenter: Yongqian Shu
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading...
-
+
P64 - Small Cell Lung Cancer/ NET - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/ NET
-
+
P64.02 - EMERGE 402 Phase 4 Observational Study: Safety and Outcomes in Patients With SCLC Receiving Treatment With Lurbinectedin
00:00 - 00:00 | Presenter: Raj Hanvesakul
- Abstract
Loading...
-
+
OA06 - Prognosis and Staging
- 08:15 - 09:15
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Staging/Pulmonary Medicine
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- 22:15 - 23:45
- 9/11/2021
- Location: Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
- Moderators:Caicun Zhou, ChunXue Bai
-
+
WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
23:13 - 23:23 | Presenter: Shun Lu
- Abstract
Loading...
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
17:30 - 17:35 | Presenter: Shengxiang (Harry) Ren
- Abstract
Loading...
